Literature DB >> 16215924

Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period.

Gary S Marshall1, Gordon G Stout.   

Abstract

The incidence of congenital cytomegalovirus (CMV) disease is dependent on the rate of virus acquisition by susceptible women in temporal proximity to pregnancy. Information about serostatus may help to identify high-risk groups and target interventions. Each year from 1991 to 2000, cord blood specimens (surrogates for maternal serum) from 100 consecutive deliveries were obtained at three hospitals. The presence of CMV immunoglobulin G antibody was correlated with demographic data. Overall, 58% of 2992 women were seropositive. After stratification by socioeconomic status (SES), nonwhite race was strongly associated with seropositivity (odds ratio, 3.0; 95% confidence interval [CI], 2.5 to 3.8), and after stratification by race, lower SES also was associated (odds ratio, 2.0; 95% CI, 1.7 to 2.3). There were no trends in seroprevalence over time in any demographic group. However, among white women 21 to 29 years of age, a significant association was found with later birth cohort. Seropositivity ranged from 40% among older, white primigravidas of upper SES to 89% among older, nonwhite, multigravid women of lower SES. These data suggest high rates of CMV transmission among nonwhite women of lower SES. Because these women tended to deliver infants at younger ages, delaying pregnancy even a few years might reduce the incidence of congenital disease. In contrast, most white, upper SES women remain susceptible to primary infection during their childbearing years. Such women born after 1975 may be more likely to reach the childbearing years with CMV immunity as compared with women born before then.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215924     DOI: 10.1055/s-2005-872590

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  8 in total

1.  Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia.

Authors:  Brian H Shirts; Konasale M Prasad; Michael F Pogue-Geile; Faith Dickerson; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2008-09-17       Impact factor: 4.939

Review 2.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

3.  Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

Authors:  Suresh B Boppana; William J Britt
Journal:  Methods Mol Biol       Date:  2021

4.  Changing patterns of cytomegalovirus seroprevalence among pregnant women in Norway between 1995 and 2009 examined in the Norwegian Mother and Child Cohort Study and two cohorts from Sor-Trondelag County: a cross-sectional study.

Authors:  Maria Lisa Odland; Kristin M Strand; Svein Arne Nordbø; Siri Forsmo; Rigmor Austgulen; Ann-Charlotte Iversen
Journal:  BMJ Open       Date:  2013-09-27       Impact factor: 2.692

5.  High susceptibility to cytomegalovirus infection of pregnant women in Flanders, Belgium.

Authors:  E Leuridan; M Ieven; N Hens; P Van Damme
Journal:  Facts Views Vis Obgyn       Date:  2012

6.  Seroprevalence of Cytomegalovirus among pregnant women and hospitalized children in Palestine.

Authors:  Tahani Neirukh; Ayda Qaisi; Niveen Saleh; Areej Abu Rmaileh; Eman Abu Zahriyeh; Lina Qurei; Firas Dajani; Taghreed Nusseibeh; Hatem Khamash; Sabri Baraghithi; Maysa Azzeh
Journal:  BMC Infect Dis       Date:  2013-11-09       Impact factor: 3.090

Review 7.  Cytomegalovirus in pregnancy and the neonate.

Authors:  Vincent C Emery; Tiziana Lazzarotto
Journal:  F1000Res       Date:  2017-02-14

8.  Cytomegalovirus (CMV) seroprevalence in the adult population of Germany.

Authors:  Raskit Lachmann; Anna Loenenbach; Tim Waterboer; Nicole Brenner; Michael Pawlita; Angelika Michel; Michael Thamm; Christina Poethko-Müller; Ole Wichmann; Miriam Wiese-Posselt
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.